Achilles Therapeutics to Lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced that it is leading a consortium that has been awarded a €4 million grant from Horizon Europe, the European Union’s key funding program for research and innovation.